RiMO-301 is under clinical development by Coordination Pharmaceuticals and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Squamous Cell Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RiMO-301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RiMO-301 is under development for head and neck squamous cell carcinoma. It was under development for prostate cancer. The drug candidate is formulated as freeze-dried powder and administered by intratumoral route. It is developed based on radio-immuno metal-organic (RiMO) technology. The drug candidate is a nanoscale metal-organic framework (nMOF) based product.
Coordination Pharmaceuticals overview
Coordination Pharmaceuticals, Inc., an immune-oncology company commercializing the nanoscale coordination polymer (NCP) technology for immunotherapy of recurrent and metastatic solid tumors. The company is headquartered in United States.
For a complete picture of RiMO-301’s drug-specific PTSR and LoA scores, buy the report here.